Donna Roy Grogan - 01 Jul 2026 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Reporting relationship: Director
Issuer ticker: CCCC
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jul 2026, 16:04:39 UTC
Prior SEC filing: 26 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Shagha Russell, Attorney-in-Fact

Key filing fact

Donna Roy Grogan filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 02 Jul 2026.

Key facts

This page summarizes Donna Roy Grogan's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2026, 16:04.

Change

Previous filing in this sequence was filed on 26 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001788455 Primary reporting owner

GROGAN DONNA ROY

Relationship: Director
Address: C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN
Signature: /s/ Shagha Russell, Attorney-in-Fact
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CCCC transaction

Common Stock

Award

Transaction value
Shares: +3,341
Change %: +4.7%
Price: $4.34^*
Shares after: 74,853
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.

Footnote F2

The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.